Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

  1. Dimopoulos, M.A.
  2. Trotman, J.
  3. Tedeschi, A.
  4. Matous, J.V.
  5. Macdonald, D.
  6. Tam, C.
  7. Tournilhac, O.
  8. Ma, S.
  9. Oriol, A.
  10. Heffner, L.T.
  11. Shustik, C.
  12. García-Sanz, R.
  13. Cornell, R.F.
  14. de Larrea, C.F.
  15. Castillo, J.J.
  16. Granell, M.
  17. Kyrtsonis, M.-C.
  18. Leblond, V.
  19. Symeonidis, A.
  20. Kastritis, E.
  21. Singh, P.
  22. Li, J.
  23. Graef, T.
  24. Bilotti, E.
  25. Treon, S.
  26. Buske, C.
  27. Show all authors +
Journal:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Year of publication: 2017

Volume: 18

Issue: 2

Pages: 241-250

Type: Article

DOI: 10.1016/S1470-2045(16)30632-5 GOOGLE SCHOLAR